Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12121529 Nucleoside phosphoramidate prodrugs

Patent 12121529 was granted and assigned to Gilead Sciences on October, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

1

Patent attributes

Patent Applicant

Gilead Sciences

1

Current Assignee

Gilead Sciences

1

Patent Jurisdiction

United States Patent and Trademark Office

1

Patent Number

Patent Inventor Names

Dhanapalan Nagarathnam1

Peiyuan Wang1

Jinfa Du1

Michael Joseph Sofia1

Date of Patent

October 22, 2024

1

Patent Application Number

185119731

Date Filed

November 16, 2023

1

Patent Citations

US Patent 6962991 Process for the synthesis of pyrazolopyrimidines

1

US Patent 7018985 Composition and method for inhibiting platelet aggregation

1

US Patent 7018989 Chemical compounds

1

US Patent 7081449 Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides

1

US Patent 7105493 Methods and compositions for treating flaviviruses and pestiviruses

1

US Patent 7105499 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

1

US Patent 7125855 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

1

US Patent 7148206 Methods and compositions for treating flaviviruses and pestiviruses

1

...

Patent Primary Examiner

Patrick T. Lewis

1

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12121529 Nucleoside phosphoramidate prodrugs

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool